Navigation Links
Silence Therapeutics and InteRNA Technologies Sign Collaboration to Develop Novel microRNA Therapeutics
Date:9/11/2011

LONDON and NIJMEGEN and UTRECHT, The Netherlands, September 12, 2011 /PRNewswire/ --

 

Silence Therapeutics plc (AIM: SLN) ("Silence"), a leading global RNA interference (RNAi) therapeutics company, and InteRNA Technologies B.V. ("InteRNA"), a biopharmaceutical company developing pathway targeted microRNA ("miRNA")-based therapeutics for cancer, today announce that they have entered into an agreement to develop novel microRNA therapeutics for the treatment of cancer. This will combine the delivery capabilities of Silence's proprietary AtuPLEX™ delivery system with InteRNA's novel microRNAs.

Silence is currently conducting a Phase I trial with Atu027 in patients with advanced solid cancer. Atu027 is based on Silence´ proprietary AtuPLEX™ delivery technology. Interim data analysis from this trial were presented at the 2011 American Society of Clinical Oncology conference and showed that Atu027 is safe and well tolerated and provided broad support for AtuPLEX™ as an effective siRNA delivery technology with the potential to overcome the delivery challenges currently associated with RNAi therapeutics.

Under the terms of the agreement, InteRNA will provide Silence with specific miRNA sequences, which Silence will formulate with its AtuPLEX™ delivery system in order to develop multiple candidate drugs.  Silence and InteRNA will undertake in vitro and in vivo studies of the candidate drugs developed under the agreement and select lead candidates for further evaluation. Silence is eligible to receive upfront fees as well as staged research payments. Further financial terms of the deal were not disclosed.

Thomas Christély, Chief Operating Officer of Silence Therapeutics'/>"/>

SOURCE Silence Therapeutics Plc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Silence Therapeutics Receives Notice of Allowance for New U.S. Patent Covering Novel Small Interfering RNA (siRNA) Delivery Technology
2. Silence Therapeutics Phase I Atu027 Data Accepted for Presentation at the American Society of Clinical Oncology 2011 Annual Meeting
3. Silence Therapeutics Issued New U.S. Patent Covering Fundamental RNA Interference Technology Currently in Several Clinical Trials
4. Silence Therapeutics Provides Year-end Update
5. Silence Therapeutics Issued New Patents Covering siRNA Sequences for RNA Interference Therapeutics
6. Silence Therapeutics and AstraZeneca Extend siRNA Development Collaboration
7. Silence Therapeutics to Merge with Intradigm Corp to Create Leading RNAi Therapeutics Company
8. Silence Therapeutics to Receive $1.9m Milestone Payment as Pfizer and Quark Commence Phase II Trial
9. Silence Therapeutics Announces Board Changes
10. Recent siRNA Research Publications Support Silence Therapeutics Combined Development Approach
11. Video: Actress and New Mom Keri Russell Joins PKIDs to Launch Silence the Sounds of Pertussis Campaign
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... , July 25, 2014  Semler Scientific, ... emerging medical risk assessment company that develops patented ... and evaluating chronic diseases, today reported financial results ... June 30, 2014. "The second ... Semler," said Doug Murphy-Chutorian , M.D., chief ...
(Date:7/25/2014)... SAN DIEGO , July 25, 2014  Arena ... it will provide a corporate update and report second ... Market opens on Friday, August 1, 2014. That same ... at 8:30 a.m. Eastern Time (5:30 a.m. Pacific Time). ... by dialing 877.643.7155 for domestic callers and 914.495.8552 for ...
(Date:7/24/2014)... , July 24, 2014  Parnell Pharmaceuticals ... compounds that will be added to Parnell,s already ... CIMTECH Pty Ltd, a biotechnology company. The compounds ... have shown promise in bone regeneration and dermal ... develop the compounds for the veterinary market with ...
Breaking Medicine Technology:Semler Reports Second Quarter 2014 Financial Results 2Semler Reports Second Quarter 2014 Financial Results 3Arena Pharmaceuticals to Host Corporate Update and Financial Results Conference Call and Webcast on Friday, August 1 2Arena Pharmaceuticals to Host Corporate Update and Financial Results Conference Call and Webcast on Friday, August 1 3Parnell Acquires License for Intellectual Property and Rights to Develop Compounds for Bone and Dermal Regeneration 2Parnell Acquires License for Intellectual Property and Rights to Develop Compounds for Bone and Dermal Regeneration 3Parnell Acquires License for Intellectual Property and Rights to Develop Compounds for Bone and Dermal Regeneration 4
(Date:7/27/2014)... 27, 2014 The European Bromine market report ... and forecast of revenue. , Bromine market in European region ... and UK. Germany and France that forms a dominant share ... derivatives in Europe. , Browse through the TOC of ... the in-depth analysis provided Browse through the TOC of the ...
(Date:7/27/2014)... Australia (PRWEB) July 27, 2014 ... in Australia is restricted to two companies, heavy ... to IBISWorld industry analyst Spencer Little, “Demand for ... due to rising health concerns, frequent anti-smoking campaigns, ... result, industry revenue is estimated to fall at ...
(Date:7/27/2014)... 2014 iFitDress.com, a well-known wedding dress ... of wedding gowns with sleeves . Furthermore, it ... they are now available with big discounts, from 20 ... that iFitDress.com is one of the big players in ... the new wedding gowns feature fine craftsmanship and charming ...
(Date:7/27/2014)... Alta Resources , a global provider of ... brands, announced today that it plans to fill more ... Florida and the Philippines. , A majority of the ... seasonal ramp-ups that require additional staffing in preparation for ... 2015. As more consumers become eligible for health-plan coverage ...
(Date:7/27/2014)... Individuals that have been involved in an ... the newly released ebook guide for how to ... help those struggling through the aftermath of personal injury due ... guide attempts to help individuals understand the legal process and ... of their doctors and an experienced attorney. , Contact ...
Breaking Medicine News(10 mins):Health News:Europe Bromine Market is Expected to Reach $111.6 Million in 2018 - New Report by MicroMarket Monitor 2Health News:Europe Bromine Market is Expected to Reach $111.6 Million in 2018 - New Report by MicroMarket Monitor 3Health News:Europe Bromine Market is Expected to Reach $111.6 Million in 2018 - New Report by MicroMarket Monitor 4Health News:Cigarette and Tobacco Product Manufacturing in Australia Industry Market Research Report Now Updated by IBISWorld 2Health News:Cigarette and Tobacco Product Manufacturing in Australia Industry Market Research Report Now Updated by IBISWorld 3Health News:Cigarette and Tobacco Product Manufacturing in Australia Industry Market Research Report Now Updated by IBISWorld 4Health News:Discounted Wedding Gowns With Sleeves Offered At iFitDress.com 2Health News:Alta Resources to Fill Approximately 2,500 Positions 2Health News:Alta Resources to Fill Approximately 2,500 Positions 3Health News:Auto Accident Personal Injury Ebook Guide Released by The Jones Firm 2
... In some cases, an apple a day may keep the ... may also do the job. A new study by ... the use of Aspirin as a preventative measure for cardiovascular ... collected data from clinical trials that looked at whether taking ...
... 5 (HealthDay News) -- Small rural hospitals in the United ... patient outcomes than larger hospitals, a new study finds. ... beneficiaries in order to assess the care provided by critical ... care beds and are located more than 35 miles from ...
... ROCHESTER, Minn. For nearly two decades, the medical ... lightning-rod topic of stem cells, in particular the controversy ... years ago successfully "reprogrammed" adult body cells to become ... over. Those redirected cells, known as induced pluripotent cells, ...
... HealthDay Reporter , TUESDAY, July 5 (HealthDay News) ... for easing low back pain in the short term, a ... mostly middle-aged, female and white, all of whom had chronic ... of either relaxation massage or structural massage were better able ...
... More breast cancer patients than previously believed may ... of Michigan Comprehensive Cancer Center study shows. Researchers ... whether cancer patients receive appropriate care and found that ... cancer patients undergo radiation treatments. The Surveillance ...
... Society invites you to attend the 2012 Symposium on ... held March 12-14, 2012, at the Marriott Baltimore Waterfront ... exciting first-time event. The symposium aims to bring ... and practice realms of the health-care community and to ...
Cached Medicine News:Health News:Higher daily dose of aspirin could play key role in preventing heart attacks for those with diabetes 2Health News:Small, Rural Hospitals Provide a Lower Quality of Care: Study 2Health News:Moving beyond embryonic stem cells: Encouragement on the horizon 2Health News:Massage Beats Meds for Lower Back Pain, Study Says 2Health News:Radiation rates for breast cancer may be underestimated, U-M study finds 2Health News:HFES sponsors 2012 Symposium on Human Factors and Ergonomics in Health Care 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: